Glenn Garmont
Investor Relations
Replay available
Predictive Oncology Inc. (NASDAQ: POAI) Q2 2024 earnings conference call, held 2024-08-14. Replay captured from the company's public earnings webcast.

Investor Relations
Chief Executive Officer and Chairman of the Board
Chief Financial Officer
Good day, and thank you for standing by. Welcome to the Predictive Oncology Second Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's prepared presentation, there will be an opportunity to ask questions. Please be advised that today's conference is being recorded. I would now like to hand the call over to your speaker, Mr. Glenn Garmont, Investor Relations. Thank you. You may begin. Welcome and thank you, everyone, for dialing into the Predictive Oncology second quarter 2024 financial results call. First, you'll hear from our chief executive officer and chairman of the board, Raymond Venari, and then our chief financial officer, Josh Blatcher, will review our financials. Certain matters discussed on this call contain forward-looking statements. These forward-looking statements reflect our current expectations and projections about future events and are subject to substantial risks, uncertainties, and assumptions about our operations and the investments we make. All statements other than statements of historical facts included in the call regarding our strategy, future operations, future financial position, future revenue and financial performance, projected costs, prospects, plans, and objectives of management are forward-looking statements. The words anticipate, believe, estimate, expect, intend, may, plan, would, target, and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our actual performance may materially differ from that contemplated by the forward-looking statements as a result of a variety of factors, including, among other things, factors discussed under the heading risk factors in our filing...